BACKGROUND & AIMS: Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective cancer chemopreventive agents. However, chronic administration of NSAIDs is associated with significant side effects, mainly of the gastrointestinal tract. Given these limitations, we synthesized phospho-sulindac (P-S; OXT-328), a novel sulindac derivative. METHODS: Here, we evaluated the safety and efficacy of P-S in preclinical models, including its mechanism of action with human colon cancer cell (HCCC) lines and animal tumor models. RESULTS: (1) Compared with sulindac, P-S is much more potent in inhibiting the growth of cultured HCCCs and more efficacious in preventing the growth of HT-29 xenografts in nude mice. P-S also prevents the growth of intestinal tumors in Apc/Min mice. (2) In combination with difluoromethylornithine (DFMO), P-S reduced tumor multiplicity in Apc/Min mice by 90%. (3) P-S is much safer than sulindac as evidenced by its in vitro toxicologic evaluation and animal toxicity studies. Mechanistically, P-S increases the intracellular levels of reactive oxygen and nitrogen species, which are key early mediators of its chemopreventive effect. Moreover, P-S induces spermidine/spermine N(1)-acetyltransferase enzymatic activity, and together with DFMO it reduces polyamine levels in vitro and in vivo. CONCLUSIONS: P-S displays considerable safety and efficacy, two pharmacologic properties that are essential for a potential cancer chemopreventive agent, and thus merits further evaluation.
BACKGROUND & AIMS: Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective cancer chemopreventive agents. However, chronic administration of NSAIDs is associated with significant side effects, mainly of the gastrointestinal tract. Given these limitations, we synthesized phospho-sulindac (P-S; OXT-328), a novel sulindac derivative. METHODS: Here, we evaluated the safety and efficacy of P-S in preclinical models, including its mechanism of action with humancolon cancer cell (HCCC) lines and animal tumor models. RESULTS: (1) Compared with sulindac, P-S is much more potent in inhibiting the growth of cultured HCCCs and more efficacious in preventing the growth of HT-29 xenografts in nude mice. P-S also prevents the growth of intestinal tumors in Apc/Min mice. (2) In combination with difluoromethylornithine (DFMO), P-S reduced tumor multiplicity in Apc/Min mice by 90%. (3) P-S is much safer than sulindac as evidenced by its in vitro toxicologic evaluation and animal toxicity studies. Mechanistically, P-S increases the intracellular levels of reactive oxygen and nitrogen species, which are key early mediators of its chemopreventive effect. Moreover, P-S induces spermidine/spermine N(1)-acetyltransferase enzymatic activity, and together with DFMO it reduces polyamine levels in vitro and in vivo. CONCLUSIONS:P-S displays considerable safety and efficacy, two pharmacologic properties that are essential for a potential cancer chemopreventive agent, and thus merits further evaluation.
Authors: Y Beazer-Barclay; D B Levy; A R Moser; W F Dove; S R Hamilton; B Vogelstein; K W Kinzler Journal: Carcinogenesis Date: 1996-08 Impact factor: 4.944
Authors: Gary A Piazza; Adam B Keeton; Heather N Tinsley; Bernard D Gary; Jason D Whitt; Bini Mathew; Jose Thaiparambil; Lori Coward; Gregory Gorman; Yonghe Li; Brahma Sani; Judith V Hobrath; Yulia Y Maxuitenko; Robert C Reynolds Journal: Cancer Prev Res (Phila) Date: 2009-05-26
Authors: Chi C Wong; Ka-Wing Cheng; Ioannis Papayannis; George Mattheolabakis; Liqun Huang; Gang Xie; Nengtai Ouyang; Basil Rigas Journal: Pharm Res Date: 2014-11-13 Impact factor: 4.200
Authors: G Xie; T Nie; G G Mackenzie; Y Sun; L Huang; N Ouyang; N Alston; C Zhu; O T Murray; P P Constantinides; L Kopelovich; B Rigas Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: George Mattheolabakis; Ioannis Papayannis; Jennifer Yang; Brandon M Vaeth; Ruixue Wang; Jela Bandovic; Nengtai Ouyang; Basil Rigas; Gerardo G Mackenzie Journal: Cancer Prev Res (Phila) Date: 2016-05-02